

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>KIRK RANDAL J</u> <hr/> (Last) (First) (Middle) <u>C/O THIRD SECURITY, LLC</u> <u>1881 GROVE AVENUE</u> <hr/> (Street) <u>RADFORD VA 24141</u> <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Fibrocell Science, Inc. [FCSC]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>09/07/2016</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Convertible Promissory Note	(1)	09/07/2016		P		236,851		(1)	(1)	Common Stock	(1)	(1)	\$236,851 ⁽¹⁾	I	by Kapital Joe ⁽²⁾
Convertible Promissory Note	(1)	09/07/2016		P		\$7,325		(1)	(1)	Common Stock	(1)	(1)	\$7,325 ⁽¹⁾	I	by Mascara Kaboom ⁽²⁾
Convertible Promissory Note	(1)	09/07/2016		P		\$3,913,979		(1)	(1)	Common Stock	(1)	(1)	\$3,913,979 ⁽¹⁾	I	by NRM VII Holdings ⁽²⁾
Convertible Promissory Note	(1)	09/07/2016		P		\$2,604,345		(1)	(1)	Common Stock	(1)	(1)	\$2,604,345 ⁽¹⁾	I	by Intrexon ⁽³⁾
Warrant to Purchase Common Stock	\$1.5	09/07/2016		P		236,851		03/08/2017 ⁽¹⁾	09/07/2021	Common Stock	236,851	(1)	236,851	I	by Kapital Joe ⁽²⁾
Warrant to Purchase Common Stock	\$1.5	09/07/2016		P		7,325		03/08/2017 ⁽¹⁾	09/07/2021	Common Stock	7,325	(1)	7,325	I	by Mascara Kaboom ⁽²⁾
Warrant to Purchase Common Stock	\$1.5	09/07/2016		P		3,913,979		03/08/2017 ⁽¹⁾	09/07/2021	Common Stock	3,913,979	(1)	3,913,979	I	by NRM VII Holdings ⁽²⁾
Warrant to Purchase Common Stock	\$1.5	09/07/2016		P		2,604,345		03/08/2017 ⁽¹⁾	09/07/2021	Common Stock	2,604,345	(1)	2,604,345	I	by Intrexon ⁽³⁾

1. Name and Address of Reporting Person*
KIRK RANDAL J

 (Last) (First) (Middle)
C/O THIRD SECURITY, LLC
1881 GROVE AVENUE

 (Street)
RADFORD VA 24141

 (City) (State) (Zip)

1. Name and Address of Reporting Person*
INTREXON CORP

(Last) (First) (Middle)

C/O LEGAL DEPARTMENT
20374 SENECA MEADOWS PARKWAY

(Street)
GERMANTOWN MD 20876

(City) (State) (Zip)

Explanation of Responses:

1. The Convertible Promissory Notes bear interest at a rate of 4% per annum with a maturity date of the earlier of (i) September 7, 2026 and (ii) 180 days after the date on which the issuer's product candidate, FCX-007, is approved by the United States Food and Drug Administration. The Notes are convertible at the option of each holder into shares of common stock at a conversion price of \$1.13625. In connection with the purchase of the Notes, each holder also received a warrant to purchase one share of the issuer's common stock per one dollar invested at a price per share of \$1.50. The Notes and Warrants each contain an ownership limitation requiring the investors to provide 61-days' advance written notice prior to conversion or exercise, respectively.

2. Randal J. Kirk controls Kapital Joe, LLC ("Kapital Joe"), Mascara Kaboom, LLC ("Mascara Kaboom") and NRM VII Holdings I, LLC (NRM VII Holdings"). Shares held by these entities may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

3. Randal J. Kirk, directly and through certain affiliates, has voting and dispositive power over a majority of the outstanding capital stock of Intrexon Corporation ("Intrexon"). Mr. Kirk may therefore be deemed to have voting and dispositive power over the shares of the issuer owned by Intrexon. Shares held by Intrexon may be deemed to be indirectly beneficially owned (as defined under Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended) by Mr. Kirk. Mr. Kirk disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

/s/ Randal J. Kirk, CEO of
Intrexon Corporation 09/09/2016

/s/ Randal J. Kirk 09/09/2016

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.